Beta results prompt early access to AI drug design software

University of Cambridge spin-out DeepMirror, software developers for the discovery of novel therapeutic drugs, has launched an Early Access Programme after a successful closed beta programme during which chemists were invited to test the software over several months. Users were able to tap into AI-driven insights to improve and accelerate molecular design across the drug discovery pipeline through a secure and user-friendly interface which makes AI-powered drug discovery as simple as using a spreadsheet.

The company’s approach, allowing R&D teams to carry out AI-driven research from day one with seamless workflow integration, reduces the need for extensive crosstalk between potential partners, and stakeholders, which can often resulting in long waiting periods with large amounts of resources used by parties involved.  

By fast-tracking the drug discovery process, for example in the Hit-to-Lead and Lead Optimisation phases, with the ability to predict relevant properties such as drug binding, (bio-activity) and toxicity, both from user data and from large proprietary curated databases, laboratory results can be used to refine predictions and generate novel drug candidates for further experimentation. This will ultimately accelerate the drug discovery process by up to 4 times, (as estimated by the Wellcome Trust and the Boston Consulting Group).

Dr Max Jakobs, Co-Founder and CEO of DeepMirror, commented: “Our mission is to make AI-powered drug design as simple as browsing the web. After 12 months of development and a successful beta testing programme, we are excited to officially launch DeepMirror to early adopters. We are inviting researchers to get in touch to use our secure and user-friendly AI platform for drug design. DeepMirror was already used on active drug discovery programmes and led to the discovery of novel lead series and inspired the synthesis of novel compounds.”

More information online